Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04PUI
|
|||
| Former ID |
DNCL003499
|
|||
| Drug Name |
BT-062
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 2 | [1], [2] | |
| Company |
Biotest Pharmaceuticals; ImmunoGen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Syndecan-1 (SDC1) | Target Info | . | [3] |
| Pathway Interaction Database | Beta3 integrin cell surface interactions | |||
| Integrins in angiogenesis | ||||
| Proteoglycan syndecan-mediated signaling events | ||||
| Syndecan-1-mediated signaling events | ||||
| Beta5 beta6 beta7 and beta8 integrin cell surface interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.